{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:51:59Z","timestamp":1789131119119,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020829","name":"Japanese Gastric Cancer Association","doi-asserted-by":"publisher","award":["JGCA-031"],"award-info":[{"award-number":["JGCA-031"]}],"id":[{"id":"10.13039\/100020829","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Osaka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2021, anamorelin, a ghrelin receptor agonist, was approved in Japan for cancer cachexia in select cancers, including gastric cancer. However, evidence regarding its efficacy and predictive factors in patients with gastric cancer remains lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational study encompassed 229 patients with unresectable, advanced, or recurrent gastric cancer and cancer cachexia who received anamorelin from 2021 to 2023 at 25 institutions affiliated with Osaka University. Body weight change at 12\u00a0weeks was the primary endpoint. Appetite, food intake, treatment compliance, and adverse events comprised the secondary endpoints. Multivariable logistic regression analyses were employed for identifying weight gain predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 229 patients (median age, 73\u00a0years), 126 completed the 12-week follow-up. The median anamorelin administration duration was 62\u00a0days. The mean weight significantly increased from baseline to 4, 8, and 12\u00a0weeks (up to\u2009+\u20090.88\u00a0kg, p\u2009&lt;\u20090.001). Moreover, appetite and food intake improved. Multivariable analysis identified baseline body mass index (BMI)\u2009&lt;\u200920\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and neutrophil-to-lymphocyte ratio (NLR)\u2009&lt;\u20094.0 as independent predictors of significant weight gain at 12\u00a0weeks. Treatment was generally well tolerated, with a 41% completion rate; 59% of the participants discontinued mainly owing to disease progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with gastric cancer-related cachexia, anamorelin was associated with significant increases in body weight and improvements in appetite. Lower BMI and lower systemic inflammation (NLR\u2009&lt;\u20094.0) were predictive of better response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-025-01637-3","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T10:00:00Z","timestamp":1751968800000},"page":"945-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study"],"prefix":"10.1007","volume":"28","author":[{"given":"Yoshitomo","family":"Yanagimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Motoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"23","key":"1637_CR1","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125(23):4294\u2013302.","journal-title":"Cancer"},{"issue":"4","key":"1637_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519\u201331.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1637_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ags3.12669","volume":"7","author":"K Nakashima","year":"2023","unstructured":"Nakashima K, Haruki K, Kamada T, Takahashi J, Nakaseko Y, Ohdaira H, et al. Usefulness of the cachexia index as a prognostic indicator for patients with gastric cancer. Ann Gastroenterol Surg. 2023;7(5):733\u201340.","journal-title":"Ann Gastroenterol Surg"},{"issue":"5","key":"1637_CR4","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s10120-021-01188-3","volume":"24","author":"Y Miyazaki","year":"2021","unstructured":"Miyazaki Y, Omori T, Fujitani K, Fujita J, Kawabata R, Imamura H, et al. Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trial. Gastric Cancer. 2021;24(5):1150\u20139.","journal-title":"Gastric Cancer"},{"issue":"4","key":"1637_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ags3.12547","volume":"6","author":"K Eto","year":"2022","unstructured":"Eto K, Yoshida N, Iwatsuki M, Iwagami S, Nakamura K, Morita K, et al. Clinical impact of perirenal thickness on short- and long-term outcomes of gastric cancer after curative surgery. Ann Gastroenterol Surg. 2022;6(4):496\u2013504.","journal-title":"Ann Gastroenterol Surg"},{"issue":"9","key":"1637_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7170","volume":"13","author":"K Takayama","year":"2024","unstructured":"Takayama K, Kojima A, Honda C, Nakayama M, Kanemata S, Endo T, et al. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan. Cancer Med. 2024;13(9): e7170.","journal-title":"Cancer Med"},{"issue":"5","key":"1637_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1637_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","volume":"89","author":"LM Forrest","year":"2003","unstructured":"Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028\u201330.","journal-title":"Br J Cancer"},{"issue":"3","key":"1637_CR9","first-page":"223","volume":"12","author":"DC McMillan","year":"2009","unstructured":"McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223\u20136.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"5","key":"1637_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534\u201340.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1637_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s10120-010-0554-3","volume":"13","author":"H Shimada","year":"2010","unstructured":"Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 2010;13(3):170\u20136.","journal-title":"Gastric Cancer"},{"issue":"12","key":"1637_CR12","first-page":"732","volume":"31","author":"M Tsunematsu","year":"2023","unstructured":"Tsunematsu M, Uwagawa T, Onda S, Shirai Y, Okui N, Matsumoto M, et al. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Support Care Cancer. 2023;31(12):732.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1637_CR13","doi-asserted-by":"publisher","first-page":"30017","DOI":"10.1038\/s41598-024-81195-3","volume":"14","author":"T Matsumoto","year":"2024","unstructured":"Matsumoto T, Cho S, Nakasya A, Nagai H, Satake H, Yasui H. Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study. Sci Rep. 2024;14(1):30017.","journal-title":"Sci Rep"},{"issue":"1","key":"1637_CR14","first-page":"118","volume":"43","author":"K Shimomura","year":"2025","unstructured":"Shimomura K, Ogata T, Maeda A, Narita Y, Taniguchi H, Murotani K, et al. Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis. Invest New Drugs. 2025;43(1):118\u201325.","journal-title":"Invest New Drugs"},{"issue":"1","key":"1637_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40780-024-00359-5","volume":"10","author":"H Fujii","year":"2024","unstructured":"Fujii H, Makiyama A, Nishimura K, Iihara H, Hirose C, Ohata K, et al. CONUT score as a predictor for anamorelin efficacy in patients with cancer cachexia receiving chemotherapy. J Pharm Health Care Sci. 2024;10(1):36.","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"1637_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12904-024-01538-9","volume":"23","author":"A Nishimura","year":"2024","unstructured":"Nishimura A, Hamauchi S, Notsu A, Fushiki K, Oshima K, Tsushima T, et al. Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia. BMC Palliat Care. 2024;23(1):214.","journal-title":"BMC Palliat Care"},{"issue":"11","key":"1637_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrc927","volume":"2","author":"MJ Tisdale","year":"2002","unstructured":"Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862\u201371.","journal-title":"Nat Rev Cancer"},{"key":"1637_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","volume":"22","author":"JM Argiles","year":"2015","unstructured":"Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100\u20136.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"1637_CR19","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1210\/jc.2004-1788","volume":"90","author":"JM Garcia","year":"2005","unstructured":"Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90(5):2920\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1637_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13732","volume":"16","author":"BJA Laird","year":"2025","unstructured":"Laird BJA, Skipworth R, Bonomi PD, Fallon M, Kaasa S, Giorgino R, et al. Anamorelin efficacy in non-small-cell lung cancer patients with cachexia: Insights from ROMANA 1 and ROMANA 2. J Cachexia Sarcopenia Muscle. 2025;16(1): e13732.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"1637_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.surg.2005.11.015","volume":"139","author":"Y Doki","year":"2006","unstructured":"Doki Y, Takachi K, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, et al. Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery. 2006;139(6):797\u2013805.","journal-title":"Surgery"},{"issue":"2","key":"1637_CR22","first-page":"774","volume":"9","author":"Y Shimizu","year":"2003","unstructured":"Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003;9(2):774\u20138.","journal-title":"Clin Cancer Res"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01637-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01637-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01637-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:44:46Z","timestamp":1769593486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01637-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01637-3","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}